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Abstract 
Prenylation of aromatic secondary metabolites is an important process involved in the biosynthesis of 
many biologically active compounds in plants and animals. Many prenylated natural products have been 
shown to exhibit very good anti-tumor, anti inflammatory and antimicrobial activities. The addition of 
prenyl side chain to an aromatic secondary metabolite often affects its pharmacological activity. The aim 
of this review is to examine the influence of the prenyl side chain on the pharmacological activities of 
some classes of aromatic secondary metabolites and the potential application of prenylation in the 
development of novel drugs 
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Prenylation is a chemical or enzymatic addition 
of an isoprenoid side chain to another molecule. 
Prenylation of aromatic secondary metabolite is 
an important process involved in the biosynthesis 
of many biologically active compounds in plants 
and animals.  Aromatic secondary metabolites 
containing prenyl side chains represent a rare 
class of natural products which are mainly found 
in plants belonging to the family of Rutaceae and 
to a lesser extent in the family of Apiaceae, 
Umbelliferae, Boraginaceae, Piperaceae, 
Compositae and Leguminosae [1].  A wide 
variety of pharmacological activities have been 
reported in plant secondary metabolites having 
prenyl residues.  
 
The addition of a prenyl chain to an aromatic 
secondary metabolite often results in a derivative 
with improved or modified pharmacological 
activity. These ‘‘hybrid’’ natural products 
represent nowadays a new frontier for the 
development of novel drugs, in particular as 
antimicrobial, anti-oxidant, anti-inflammatory and 
anti-cancer agents [1]. The prenyl side chains 
are of different carbon length (Figure 1). Four 
types of prenyl side chain have been identified 
based on the size of the carbon; C5 
(isopentenyl), C10 (geranyl), C15 (farnesyl) and 
C20 (geranylgeranyl). Compounds having the 
isopentenyl and the geranyl side chains are more 
abundant in nature while those with farnesyl and 
geranylgeranyl are rare. The prenyl skeleton is 
attached to the aromatic compound directly or 
through another atom such as oxygen, nitrogen 
or sulphur. The carbon and oxy prenylated 
metabolites are quite abundant while the later 
two are less common. 
 
The biosynthesis of prenylated aromatic 
secondary metabolites  involves the coupling of 
products from the shikimic acid and the 
mevalonic acid pathways.  The latter produces 
the prenyl group while the former produces the 
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aromatic compound. The two products are linked 
together by prenyl tranferase enzymes [2]. Many 
prenylated natural products have been isolated 
long ago, but it was only in the last decade that 
this class of compounds received tremendous 
research attention particularly, in the aspect of 
their pharmacological activity evaluation.  Many 
review papers published on this subject area 
have focused on the isolation, classification and 
general pharmacology of prenylated natural 
products. In this review however, we have 
examined the influence of the prenyl group on 
the pharmacological activities of some classes of 
aromatic secondary metabolites and the potential 
application of prenylation in development of 
novel drugs. 
 
INFLUENCE OF THE PRENYL SIDE CHAIN ON 




Prenylated acridones are mainly found in citrus 
plant family of Rutaceae. They have been shown 
to possess various pharmacological activities, 
such as cytotoxity [3,4] , antiviral [5] and 
antimalaria activities [6,7].  Itoigawa and co 
workers [8] evaluated 17 acridone alkaloids 
isolated from plants of the genera Citrus, 
Glycosmis and Severinia (Rutaceae) for their 
anti-tumor-promoting activity in the short-term in 
vitro assay of Epstein–Barr virus early antigen 
(EBV-EA) activation. They discovered that the 
prenylated acridones 3-10 (Figure 2) have 
remarkably more potent activities compared to 
the non prenylated compounds with the same 
basic structure. Glycocitrine-II (3) and 
Omethylglycocirine- II (5) exhibited  more potent 
inhibitory activity (IC50 of 280 and 281 mol 
ratio/32 pmol TPA respectively) when compared 
to 1,3-Dihydroxy-10-methylacridone (1) which do 
not  have prenyl side chain(IC 50 of 368 mol 
ratio/32 pmol TPA). 
 
Similarly the prenylated pyranoacridones (6– 9) 
exhibited more potent antitumor promoting 
activity (IC50 276–302 mol ratio/32 pmol TPA), 
compared to des-N-methylnoracronycine (2) 
which has the same basic structure but lack the 
prenyl side chain (IC50 437 mol ratio/32 pmol 
TPA). Based on the results of this investigation, 
the group synthesized 1,3-dihydroxy-10-methyl-
2,4-diprenylacridone (10) a novel compound 
which exhibited a marked inhibitory effect on 
mouse skin tumor promotion in an in vivo two-
stage carcinogenesis test (52% reduction in 
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Figure 2: Prenylated and non-prenylated acridones      
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indicate that the prenyl group is an important 
structural feature for good anti tumor promoting 
activity of the acridone molecule and can be 
exploited in new drug development. 
 
Prenylated coumarins  
 
This class of compounds is commonly found in 
citrus plants, family Rutaceae. They frequently 
occur as oxyprenylated metabolites. The 
oxyprenylated coumarins posses good anti-
inflammatory and anticancer properties. The first 
oxyprenylated secondary metabolite to be 
reported in literature is a coumarin, auraptene 
(11), isolated in 1930 from Citrus aurantium L. 
(rutaceae) and structurally characterized by 
Kariyone and Matsuno [9]. It was later 
discovered to be present in other plants like 
Zanthoxylum schinifolium [10] and Paliurus 
ramosissimus [11]. Auraptene was shown to be 
effective in preventing the chemical 
carcinogenesis in various rodent models 
including skin [12], tongue [13], liver [14], and 
colon carcinogenesis[15]. Another natural 
occurring prenyloxy coumarin is umbelliprenin  
(7-trans, trans-farnesyloxy coumarin) (12), 
isolated from Ferula persica [16]. It was shown to 
posses antioxidant, anti-inflammatory and 
lipoxygenase inhibitory activities [17]. Based on 
the foregoing, the effects of prenyl group on 
anticancer and anti-inflammatory activities of 
coumarins were investigated. Devji and Co-
workers [18] synthesized a series of prenylated 
and non prenylated hydroxycoumarin derivatives 
and evaluated their activity against human 
pancreatic PANC-1 cancer cells under nutrient-
deprived conditions. The results of the 
investigation showed that the prenylated 
coumarins 18 - 22 (Figure 3) exhibit higher 
cytotoxic activity against the PANC-1 cancer 
cells than 17, while 13-16 do not show any 
appreciable activity. The results also showed that 
the longer the prenyl side side chain the higher 
the cytotoxic activity. This study led to the 
discovery of a novel geranylgeranylated 
hydroxycoumarin (21) which exhibited 100 % 
preferential cytotoxicity against PANC-1 cells 
under nutrient-deprived medium at 6.25 µM 
making this compound a powerful new lead 
structure for the development of novel anti- 
cancer  agents. In another related work 
conducted [19], O-prenylated derivatives 
involving farnesyloxy, geranyloxy and 
isopentenyloxy substituents at positions 3, 4, 5, 
6, 7 and 8 of coumarin ring were synthesized and 
their lipoxygenase inhibitory activities  together 
with the SAR studies were evaluated. The results 
obtained from these experiments showed that 
among the three groups of synthetic O-
prenylated coumarins, farnesyloxy derivatives 
displayed the best inhibitory activity against 
soybean15-lipoxygenase (IC 50 : 1.7 to 5.8µm) 
while the isopentenyl derivatives displayed the 
least (IC50 : 39.8 to 69.4 µM). The results further 
showed that the Lipoxygenase inhibitory potential 
of the coumarins is influenced by the presence 
and length of prenyl side chain and it decreases 





Watjen and co-workers [20] analyzed the 
antioxidative potential and cytotoxic effects of 
two prenylflavonoids (Figure 4), licoflavone C 
(24) and and isobavachin (26) in comparison to 
their non prenylated analogues, apigenin (23) , 
liquiritigen (25) and apigenin glucoside (27). 
They discovered that compounds 24 and 26 
showed good cytotoxic activity against C6 glioma 
and H4IIE hepatoma cells with IC50 of 42 ± 5 and 
96 ± 19 µmol/L respectively. In contrast, 
compounds 23, 25 and 26 did not show any 
significant cytotoxic activity against the two 
cancer cell lines. This indicates that the insertion 
of prenyl group (isopentenyl) at position 8 
enhances the cytotoxic activity of apigenin and  
liquiritigen. This property may probably be 
extended to other flavonoids. Further research is 




Prenylated chalcones are commonly found in 
hops (cannabaceae) and few other plants. This 
class of compounds exhibit good antioxidant 
activity. The ability of some prenylated  and non 
prenylated chalchones to inhibit the in vitro 
oxidation of human low density lipoprotein (LDL) 
was investigated by Miranda and Co workers 
[21]. The oxidation of LDL was assessed by the 
formation of conjugated dienes and thiobarbituric 
acid reactive substances (TBARS) and 
Tryptophan fluorescence. They found that the 
prenylated  chalcones (29, 30) inhibited the 
oxidation of LDL (50µg protein/ml) at 
concentration of 5 and 25 µm while the non 
prenylated chalcone (28) (Figure 5) exerted pro-
oxidant activity on LDL. This is an indication that 
the presence of prenyl group significantly 
enhances the antioxidant activity of hydroxylated 
chalcones. 
 
Prenylated cinnamic acids 
 
Artepillin C (31) and 4 geranyloxyferulic acid (34) 
are prenylated cinnamic acid derivatives with 
interesting and valuable pharmacological 
properties. Artepillic C (3,5-diprenyl-4-
hydroxycinnamic acid) was isolated from green 
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Brazilian propolis which is produced from 
exudates of Baccharis dracunculifolia [22,23]. 
Artepilli C possesses very good anti inflammatory 
property [24]. Paulino and Co workers [24] 
investigated the anti-inflammatory effects, 
absorption, and bioavailability of artepillin C in 
mice. The mice were subjected to: carrageenan- 
induced paw oedema (300 μg/paw), 
carrageenan-induced peritonitis, and prosta-
glandin E2 determination.  In addition, in vitro 
nitric oxide production by RAW 264.7 cells and 
NF-κB activity in HEK 293 cells were also 
measured. The group reported that in vivo 
Artepillin C produced a maximal inhibition of 38% 
after 360 min on paw oedema, decreased the 
number of neutrophils during peritonitis (IC50: 0.9 
(range 0.5 – 1.4) mg/kg) as well as decreased 
prostaglandin E2 by 29±3% and 58±5% at 1 and 
10 mg/kg, respectively, with a mean ID50 of 8.5 
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 Figure 3: Structure of prenylated and non-prenylated coumarins 
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Figure 5: Structures of Prenylated and non prenylated chalcones (28-30) and cinnamic acids (31-34) 
 
(range 8.0 – 8.7)mg/kg). Similarly, in in vitro 
models, it decreased nitric oxide production by 
RAW264.7 cells with a mean IC50 of 8.5 (range 
7.8 – 9.2) μM. This high anti inflammatory activity 
displayed by this compound could probably be 
due to the presence of diprenyl group attached at 
position 3 and 5  of the molecule because the 
non prenylated 4–hydroxy cinnamic acid  scaffold 
(31)  (Figure 5) has been shown to possess only 
mild to moderate anti inflammatory activity [25]. 
In addition to its anti-inflammatory property, 
artepillin C has also been shown to exhibit 
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remarkable antimicrobial [26] anticancer [27-29] 
and antioxidant activities [30,31], which may also 
be related to the presence of the diprenyl  group.   
4-Geranyloxyferulic acid (34) (Figure 5) was 
isolated from the bark of Acronychia baueri 
Schott, an Australian plant belonging to the 
family of Rutaceae [32]. This compound was 
shown to display good antitumor properties, 
particularly against colon related cancers [33-35]. 
This valuable pharmacological property has not 
been reported in the unprenylated ferulic acid 
(33) (Figure 5). This indicates that the presence 
of geranyloxy residue may have been partly 
responsible for the good anticancer property of 
the molecule.  
 
MECHANISM OF ACTION 
 
One possible mechanism by which a prenyl 
group may enhance or modify the 
pharmacological activity of aromatic secondary 
metabolite is through improvement of lipophilicity. 
The introduction of a prenyl side chain into a 
molecule increases its lipophilicity which could 
modify its pharmacological activity through 
enhanced access, affinity and interaction with the 
lipophilic membrane [36]. Another possible 
mechanism is the inhibition of ras signal 
transduction. Ras proteins constitute an 
important part of intracellular signal transduction 
system. Ras proteins are activated by 
attachment of farnesyl moiety. Activated RAS 
proteins are involved in regulating many cell 
functions, such as proliferation, differentiation 
and inflammation. RAS mutations are found in 
approximately one-third of human cancers, most 
especially in pancreatic and colorectal 
carcinomas [37].  Some prenylated aromatic 
compounds particularly, farnesyl thiosalicylic acid 
(35) (Figure 6) and its analogues were shown to 






Figure 6: Structure of farnesylthiosalicylic acid  
 
with the binding of RAS to its plasma membrane 
anchor protein [38-39]. Besides these two 
mechanisms, the prenyl moiety could exert its 
activity by allowing indigenous molecules to 
identify specific but still unknown biological 
targets in human and animals [40]. Further 
studies are, however, needed to understand the 
detailed mechanisms by which prenyl group 
influences pharmacological activity. 
 
FARNESYL THIOSALiCYLIC  ACID - AN 
EXAMPLE OF PRENYLATION IN DRUG  
DEVELOPMENT  
 
Salirasib (S-trans, trans-farnesylthiosalicylic acid, 
FTS, Concordia Pharmaceuticals, Ft. 
Lauderdale, FL) is a molecule in which the 
hydroxyl group of salicylic acid was replaced with 
a S-farnesyl group.  FTS interferes with the 
interactions of Ras with its binding site which 
results in dislodgment of Ras from the cell 
membrane, thus preventing Ras activation and 
signal transduction cascade. FTS has been 
shown to inhibit the in vitro Ras dependent 
proliferation of different cancer cell lines including 
glioblastoma [41], pancreatic carcinomas [42], 
ovarian carcinomas [43]  colon carcinomas [44]  
and prostate cancer cells [45]. FTS is currently in 
clinical trial. Results from the phase 1 clinical trial 
showed that it is effective, relatively safe and 
pharmacokinetics data suggest the possibility of 
this molecule emerging as the first available 
orally active Ras antagonist [46]. It is now 
evident that the insertion of prenyl group into an 
aromatic compound is a viable means through 
which new drugs with improved pharmacological 
activities could be developed. The challenge now 
is to extend such studies to cover wide variety of 
aromatic compounds including the existing drugs 




Quite a large number of prenylated aromatic 
metabolites have been isolated as natural 
products while few were synthesized. Many 
studies about their pharmacological activities 
have been carried out in the last decade. Results 
from these investigations have clearly 
demonstrated how the presence of prenyl group 
improved their pharmacological activities; thus 
indicating the possibility of aromatic secondary 
metabolites  as potential source of novel drugs  
for the treatment of diseases such as cancer, 
inflammation and microbial infections. The 
discovery of farnesyl thiosalicylic acid as Ras 
antagonist, further buttress the capacity of 
prenylation of aromatic compounds in 
development of new drugs. It is anticipated that 
future research in this area will cover a wider 
range of aromatic compounds besides the 
alkaloids and phenylpropanoids.  Moreover, 
further studies are needed to understand the 
detailed mechanisms by which prenyl group 
influence pharmacological activity. This could 
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provide a basis for rapid development of drug for 
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